Evidence map›Paper›PMID 29050493›Full record

ArticleBiological research for nursing2018

Serum BDNF Is Positively Associated With Negative Symptoms in Older Adults With Schizophrenia.

Sasha S Binford, Erin M Hubbard, Elena Flowers, Bruce L Miller, Heather Leutwyler

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biological research for nursing, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sasha S Binford1 Memory and Aging Center, University of California, San Francisco, CA, USA.
Erin M Hubbard2 Department of Physiological Nursing, University of California, San Francisco, CA, USA.
Elena Flowers3 Department of Physiological Nursing, Institute for Human Genetics, University of California, San Francisco, CA, USA.
Bruce L Miller1 Memory and Aging Center, University of California, San Francisco, CA, USA.
Heather Leutwyler2 Department of Physiological Nursing, University of California, San Francisco, CA, USA.
University of California, San Francisco · USUniversity Memory and Aging Center · US

Funding

VARC CoreP30AG044281 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KENNETH E. COVINSKY, MICHAEL A. STEINMAN · 2013 to 2026
$19.9M
Clinical and Transtional Science InstituteKL2TR000143 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$11.9M
Biobehavioral Research Training Program in Symptom ScienceT32NR016920 · NINR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MIASKOWSKI, CHRISTINE A., WEISS, SANDRA JEAN · 2017 to 2021
$2.4M
Symptom Management Faculty Scholars ProgramP30NR011934 · NINR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MIASKOWSKI, CHRISTINE A. · 2009 to 2010
$1.5M
Factors Associated to Poor Mobility in Older Adults with SchizophreniaK23AG044438 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEUTWYLER, HEATHER CHRISTINE · 2014 to 2016
$473k
NCATS NIH HHS KL2 TR000143NIA NIH HHS K23 AG044438NIA NIH HHS P30 AG044281NINR NIH HHS P30 NR011934NINR NIH HHS T32 NR016920
6 · The paper itself

Abstract

objectivesOlder adults with chronic schizophrenia are at greater risk for functional disability and poorer health outcomes than those without serious mental illness. These individuals comprise 1-2% of the elderly population in the United States and are projected to number approximately 15 million by 2030. The symptoms of schizophrenia can be disabling for individuals, significantly reducing quality of life. Often, the negative symptoms (NS) are the most resistant to treatment and are considered a marker of illness severity, though they are challenging to measure objectively. Biomarkers can serve as objective indicators of health status. Brain-derived neurotrophic factor (BDNF) is a potential biomarker for schizophrenia and may serve as an important indicator of illness severity.

methodsA cross-sectional study with 30 older adults with chronic schizophrenia. Participants were assessed on serum levels of BDNF and psychiatric symptoms (Positive and Negative Syndrome Scale). Pearson's bivariate correlations (two-tailed) and linear regression models were used.

resultsA significant positive association ( p < .05) was found between higher serum levels of BDNF and greater severity for the NS items of passive, apathetic, social withdrawal, and emotional withdrawal. In multivariate analyses, the association remained significant.

conclusionsAlthough the association between BDNF and NS was not in the expected direction, the data corroborate findings from previous work in patients with schizophrenia. It is possible that higher serum levels of BDNF reflect compensatory neuronal mechanisms resulting from neurodevelopmental dysfunction.

Indexed as

AgedAged, 80 and overBehavioral SymptomsBiomarkersBrain-Derived Neurotrophic FactorCross-Sectional StudiesFemaleHumansMaleMiddle AgedSchizophreniaUnited StatesBiomarkersBrain-Derived Neurotrophic FactorBDNFnegative symptomsschizophrenia

Identifiers

PMID29050493
PMCPMC5942501
OpenAlexW2793710085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.